483
Daito Pharmaceutical Co., Ltd.Daito Pharmaceutical Co., Ltd. – FDA 483, Dec 19, 2023
Record Details
An FDA inspection of Daito Pharmaceutical Co., Ltd. in Toyama-City, Japan, revealed significant deficiencies in manufacturing controls and quality assurance. The firm lacked adequate written procedures for equipment cleaning and cross-contamination monitoring, and failed to qualify non-pharmacopeia standards used for raw material testing against USP reference standards. These issues indicate a lack of robust controls to ensure drug product quality and purity.
View Company Profile
ID · cf452e09-1736-4778-8b0b-99a60c8c3188
Other documents for Daito Pharmaceutical Co., Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.